These preclinical findings support clinical trial results showing that tirzepatide, a dual GIPR/GLP-1R agonist, exhibits greater anti-obesity effects than GLP-1 receptor agonists alone. This evidence concerns the gene GIPR and obesity due to melanocortin 4 receptor deficiency.